Condition (MeSH)
Tinea Pedis
ClinicalTrials.gov lists 69 trials for Tinea Pedis or a narrower condition beneath it. Sun Pharmaceutical Industries, Inc. has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
69 of the 69 trials are tagged with Tinea Pedis itself; the rest are tagged with a narrower condition beneath it.
When did Tinea Pedis trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 5 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 3 |
| 2020 | 3 |
| 2019 | 6 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 5 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tinea Pedis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 17 |
| Phase 3 | 19 |
| Phase 4 | 4 |
| Not applicable | 11 |
| Observational | 4 |
How many Tinea Pedis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Completed | 52 |
| Terminated | 3 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tinea Pedis trials? (14)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sun Pharmaceutical Industries, Inc. | 8 |
| Merz North America, Inc. | 4 |
| AmDerma | 3 |
| Biolab Sanus Farmaceutica | 2 |
| DermBiont, Inc. | 2 |
Showing 5 of 14 sponsors.
Which drugs are being tested for Tinea Pedis? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TERBINAFINE HYDROCHLORIDE (1%) | 4 |
| Dapaconazole | 3 |
| Clotrimazole | 2 |
| Butenafine HCl 1% (BAY1896425) | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ketoconazole 2% | 4 |
| Vehicle Foam | 3 |
| Econazole Nitrate Foam 1% | 3 |
| Econazole Nitrate Cream 1% | 3 |
| Luliconazole Cream 1% | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tinea Pedis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Chest pain | 3 | 2 |
| Cellulitis | 2 | 1 |
| Abscess | 1 | 1 |
| Anal Abscess | 1 | 1 |
| Appendicitis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Tinea Pedis? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. | Journal of drugs in dermatology : JDD | 2011 | Yes |
| Tea tree oil in the treatment of tinea pedis. | The Australasian journal of dermatology | 1992 | Yes |
| Tinea pedis and erythrasma in Danish recruits. Clinical signs, prevalence, incidence, and correlation to atopy. | Journal of the American Academy of Dermatology | 1986 | Yes |
| High prevalence of foot diseases in Europe: results of the Achilles Project. | Mycoses | 2003 | No |
| Dermatologic disorders of the foot. | Clinics in sports medicine | 1994 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.